Biotech Showcase Sessions

Flash Presentation During Coffee Breaks

As part of a new initiative at CTAD 2025, we are hosting dedicated Biotech Showcase Sessions — dynamic flash presentation slots where selected biotech companies will: 

  • Present their work in 3-minute / 3-slide lightning talks
  • Engage in 3 minutes of live Q&A with moderators and attendees
  • Gain expert feedback and investor attention
  • Build high-value connections with leaders in AD clinical trials 

Session 1 – Artificial Intelligence and Digital Innovation

Focus: AI platforms, digital biomarkers, virtual and mobile cognitive assessment.

Tuesday, December 2nd – 10:40 a.m. to 11:10 a.m.

  1. Prima Mente – AI neuroscience integrating data generation and clinical translation
  2. Tolion Health – AI-driven brain health and longevity guidance app
  3. Unlearn.AI – Digital twin platform for modern Alzheimer’s trials
  4. Indivi AG – Adaptive cognitive assessments with dynamic difficulty adjustment 

Session 2 – Digital and Neurotechnology-Based Therapeutics 

Focus: novel neurotech and at-home stimulation tools. 

Tuesday, December 2nd – 4:00 p.m. to 4:30 p.m.

  1. Nuuron GmbH – Ultra-high-frequency visual stimulation for memory enhancement
  2. Clarity Health Technologies – VR-integrated 40Hz sensory stimulation
  3. REGEnLIFE – Photomedical neurotechnology for brain–gut stimulation
  4. Cumulus Neuroscience – Remote digital biomarkers for trial efficiency 

Session 3 – Blood-Based Diagnostics and Biomarkers 

Focus: plasma and proteomic biomarker innovation. 

Wednesday, December 3rd – 10:55 a.m. to 11:25 a.m.

  1. Diadem Inc. – AlzoSure® Predict plasma test (unfolded p53)
  2. Veravas – VeraBIND Tau plasma assay for active tau pathology
  3. betaSENSE GmbH – Immuno-infrared sensor detecting misfolded proteins
  4. Taudia – Detection of low-abundance biomarkers for patient screening 

Session 4 – Multiomics and Precision Diagnostics 

Focus: Omics-based platforms and biomarker qualification. 

Wednesday, December 3rd – 3:50 p.m. to 4:20 p.m.

  1. AgenT – Multiomics blood biomarkers for Alzheimer’s drug development
  2. Washington University in St. Louis – Proteomic classifier for precision diagnosis
  3. Fujirebio/ADx NeuroSciences – ADxPLORER qualified assays for early biomarker access
  4. Ricoh Biosciences – iPSC neuron panel for biomarker discovery 

Session 5 – Next-Generation Therapeutics 

Focus: novel small molecules, peptides, and new treatment modalities. 

Thursday, December 4th– 10:40 a.m. to 11:10 a.m.

  1. ProNeurogen Inc. – PNA5 first-in-class therapy for vascular dementia
  2. Galimedix Therapeutics – GAL-101 Phase 1 oral small molecule
  3. ChainGen Bio – BrainPortal peptides for blood–brain barrier transport
  4. Anavex Life Sciences – Oral Blarcamesine Phase IIb/III trial results 

Session 6 – Late-Stage Biotech and Industry Innovations 

Focus: advanced clinical programs and scalable biomarker platforms. 
 

Thursday, December 4th – 3:50 p.m. to 4:20 p.m.

  1. AriBio Co. Ltd. – AR1001 Phase 3 neurodegeneration program (POLARIS-AD)
  2. Beckman Coulter Inc. – Blood-based biomarker solutions for AD diagnostics
  3. Advanced Brain Monitoring – BEAM™ mobile EEG/ERP platform for cognitive assessment
  4. Sunbird Bio – EV-based plasma assay platform for non-invasive detection of modified αSyn species